Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of MDKG-TE1D in spinocerebellar degeneration and MSA-C
jRCT2012260055Phase 3Not yet recruiting
- Sponsor
- mediVR
- Start
- Oct 2026
- Countries
- 1
01
Overview
Phase 3 trial in spinocerebellar ataxia (SCA) and multiple system atrophy (MSA), sponsored by mediVR. Primary endpoint: TUG Comfortable Speed. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
spinocerebellar ataxia (SCA)multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2012260055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2012260055.